NewLink Genetics

NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.
Type
Public
HQ
Ames, US
Founded
1999
Size (employees)
210 (est)+126%
NewLink Genetics was founded in 1999 and is headquartered in Ames, US

NewLink Genetics Office Locations

NewLink Genetics has offices in Ames, Austin, Devens
Ames, US
Austin, US
Devens, US

NewLink Genetics Metrics

NewLink Genetics Summary

Market capitalization

$445 M

Closing share price

$15
NewLink Genetics's current market capitalization is $445 M.

NewLink Genetics Financials

NewLink Genetics's revenue is $68.5 M in FY, 2015 which is 60.31% decrease from the previous period.
FY, 2015FY, 2014FY, 2013

Revenue

$68.5 M$173 M

Revenue growth, %

-60.3%

Operating income

$-33.6 M$118 M$-139 M

Operating expense total

$102 M$55 M$147 M

Net Income

$-40.4 M$103 M$-137 M

Operating cash flow

$5.22 M$129 M$61.3 M

NewLink Genetics Market Value History

NewLink Genetics Company Life

You may also be interested in